{"id":"NCT01743989","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.","officialTitle":"A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-15","primaryCompletion":"2020-07-08","completion":"2020-07-08","firstPosted":"2012-12-06","resultsPosted":"2021-07-15","lastUpdate":"2021-07-15"},"enrollment":620,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)"],"interventions":[{"type":"DRUG","name":"Nilotinib","otherNames":["AMN107"]}],"arms":[{"label":"Nilotinib 24-month treatment","type":"EXPERIMENTAL"},{"label":"Nilotinib 36-month treatment","type":"EXPERIMENTAL"},{"label":"Not randomized","type":"EXPERIMENTAL"}],"summary":"This study aimed to assess the optimal duration of nilotinib 300 mg twice daily (BID) consolidation treatment in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), in order that patients remained in treatment-free remission (â‰¥MR4.0) without molecular relapse 12 months after starting the Treatment-Free Remission (TFR) phase.","primaryOutcome":{"measure":"Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase","timeFrame":"12 months after entering the TFR phase, which is after 36 months from study treatment start for Nilotinib 24-month treatment arm and after 48 months from study treatment start for Nilotinib 36-month treatment arm","effectByArm":[{"arm":"Nilotinib 24-month Treatment","deltaMin":31.9,"sd":null},{"arm":"Nilotinib 36-month Treatment","deltaMin":37.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.383"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":208,"countries":["Austria","Belgium","Bulgaria","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Italy","Norway","Poland","Portugal","Romania","Serbia","Slovakia","Slovenia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["34123791"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":120},"commonTop":["Hypercholesterolaemia","Pruritus","Rash","Hypertension","Lipase increased"]}}